Clinical Trials

Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis

Basel, October 7, 2021 — Novartis announced today it will present 41 abstracts at the upcoming 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place digitally on October 13-15, 2021. The data being presented spans a comprehensive MS portfolio, emphasizing the company’s commitment to…

NeuroscienceClinical Trials
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program

Basel, September 23, 2020 – Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA). The FDA has acknowledged the potential of AVXS-101 IT in this…

Drug DevelopmentClinical TrialsAd Hoc
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19

Basel, May 27, 2021 — Novartis and Molecular Partners announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will conduct the clinical trial program for ensovibep, with Molecular Partners as sponsor of…

Reimagine MedicineDrug DevelopmentClinical Trials
Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021

Basel, June 2, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx® (secukinumab) significantly delayed time to flare vs placebo (P<.001) in pediatric patients with juvenile psoriatic arthritis (JPsA) and enthesitis-related…

Reimagine MedicineClinical TrialsChronic Illness
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3

Basel, December 11, 2019 — MONALEESA-3 data published today in The New England Journal of Medicine (NEJM) shows Kisqali® (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival, with an almost 30% reduction in risk of death compared to fulvestrant alone, in postmenopausal women with hormone-receptor…

OncologyInnovationClinical TrialsCancer
Discovery

Toward improving the health and longevity of transplanted organs

Novartis researchers are working to extend the life of organ transplants

InnovationMedical InnovationsNovartis Institutes for BioMedical ResearchClinical ResearchClinical Trials
Discovery

Researchers boost understanding of T-cell therapy in blood cancer

Novartis investigators find genetic explanations for why some young patients relapse.

CancerCell and Gene TherapyNovartis Institutes for BioMedical ResearchClinical ResearchClinical Trials
Discovery

Cancer research drives breast cancer treatment forward

Novartis team perseveres to develop more personalized approach to breast cancer therapy.

CancerInnovationNovartis Institutes for BioMedical ResearchClinical Trials
Discovery

Can data from a heart disease trial lead to a potential cancer treatment?

Novartis researchers are learning how a novel approach to immunotherapy could help treat cancer.

CancerNovartis Institutes for BioMedical ResearchOncologyScientific ResearchClinical Trials
People and Culture

Going the extra mile to keep clinical trials on track during the COVID-19 pandemic

A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

COVID-19DigitalClinical ResearchClinical TrialsClinical ScienceDrug Development
Patient Perspectives

Turning the sound up on patient voices in lung cancer research and development

Global Oncology Patient Insights Panels (GOPIPs) are giving patients and advocates a critical voice in advancing lung cancer trials.

Disease AwarenessOncologyPatient VoicesClinical TrialsDrug Development
Patient Perspectives

T.J. Sharpe on why clinical trials matter

Melanoma survivor T.J. Sharpe discusses the importance of clinical trials to help raise awareness among the community.

CancerLiving With DiseaseOncologyPatient VoicesClinical Trials